Serum paraoxonase level and paraoxonase polymorphism in patients with acromegaly

References

• Colao A, Merola B, Ferone D, Lombardi G. Acromegaly. J Clin Endocrinol Metab 1997;82(9):2777–81. doi: 10.1210/jcem.82.9.4257
   PubMed Web of Science ®Google Scholar
• Dos Santos Silva CM, Lima GA, Volschan IC, Gottlieb I, Kasuki L, Neto LV, Gadelha MR. Low risk of coronary artery disease in patients with acromegaly. Endocrine 2015;50(3):749–55. doi: 10.1007/s12020-015-0628-4
   PubMed Web of Science ®Google Scholar
• Cannavo S, Almoto B, Cavalli G, Squadrito S, Romanello G, Vigo MT, et al. Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography. J Clin Endocrinol Metab 2006;91(10):3766–72. doi: 10.1210/jc.2005-2857
   PubMed Web of Science ®Google Scholar
• Bogazzi F, Battolla L, Spinelli C, Rossi G, Gavioli S, Di Bello V, et al. Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J Clin Endocrinol Metab 2007;92(11):4271–7. doi: 10.1210/jc.2007-1213
   PubMed Web of Science ®Google Scholar
• Otsuki M, Kasayama S, Yamamoto H, Saito H, Sumitani S, Kouhara H, et al. Characterization of premature atherosclerosis of carotid arteries in acromegalic patients. Clin Endocrinol (Oxf) 2001;54(6):791–6. doi: 10.1046/j.1365-2265.2001.01281.x
   PubMed Web of Science ®Google Scholar
• Fleseriu M. Insight into cardiovascular risk factors in patients with acromegaly. Endocrine 2014;47(1):1–2. doi: 10.1007/s12020-013-0157-y
   PubMed Web of Science ®Google Scholar
• Akutsu H, Kreutzer J, Wasmeier G, Ropers D, Rost C, Möhlig M, et al. Acromegaly per se does not increase the risk for coronary artery disease. Eur J Endocrinol 2010;162(5):879–86. doi: 10.1530/EJE-09-0945
   PubMed Web of Science ®Google Scholar
• Ragonese M, Alibrandi A, Di Bella G, Salamone I, Puglisi S, Cotta OR, et al. Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction. Endocrine 2014;47(1):206–12.
   PubMed Web of Science ®Google Scholar
• Clayton RN. Cardiovascular function in acromegaly. Endocr Rev 2003;24:272–7. doi: 10.1210/er.2003-0009
   PubMed Web of Science ®Google Scholar
• Muller G, Goettsch C, Morawietz H. Oxidative stress and endothelial dysfunction. Hamostaseologie 2007;27(1):5–12.
   PubMedGoogle Scholar
• Yarman S, Ozden TA, Gökkuşu C. The evaluation of lipid peroxidation and acute effect of octreotide on lipid peroxidation in patients with active acromegaly. Clin Chim Acta 2003;336(1–2):45–8. doi: 10.1016/S0009-8981(03)00328-0
   PubMed Web of Science ®Google Scholar
• Brown-Borg HM, Rakoczy SG, Romanick MA, Kennedy MA. Effects of growth hormone and insulin-like growth factor-1 on hepatocyte antioxidative enzymes. Exp Biol Med (Maywood) 2002;227(2):94–104.
   PubMed Web of Science ®Google Scholar
• Nishizawa H, Handayaningsih AE, Iguchi G, Cho Y, Takahashi M, Yamamoto M, et al. Enhanced oxidative stress in GH-transgenic rat and acromegaly in humans. Growth Horm IGF Res 2012;22(2):64–8. doi: 10.1016/j.ghir.2012.02.001
   PubMed Web of Science ®Google Scholar
• Anagnostis P, Efstathiadou ZA, Gougoura S, Polyzos SA, Karathanasi E, Dritsa P, et al. Oxidative stress and reduced antioxidative status, along with endothelial dysfunction in acromegaly. Horm Metab Res 2013;45(4):314–8.
   PubMed Web of Science ®Google Scholar
• Higashi Y, Sukhanov S, Anwar A, Shai SY, Delafontaine P. IGF-1, oxidative stress and atheroprotection. Trends Endocrinol Metab 2010;21(4):245–54. doi: 10.1016/j.tem.2009.12.005
   PubMed Web of Science ®Google Scholar
• Ozkan C, Altinova AE, Cerit ET, Yayla C, Sahinarslan A, Sahin D, et al. Markers of early atherosclerosis, oxidative stress and inflammation in patients with acromegaly. Pituitary 2014;18(5):621–9. doi: 10.1007/s11102-014-0621-6
   Web of Science ®Google Scholar
• Sukhanov S, Snarski P, Vaughn C, Lobelle-Rich P, Kim C, Higashi Y, et al. Insulin-like growth factor I reduces lipid oxidation and foam cell formation via downregulation of 12/15-lipoxygenase. Atherosclerosis 2015;238(2):313–20. doi: 10.1016/j.atherosclerosis.2014.12.024
   PubMed Web of Science ®Google Scholar
• Succurro E, Andreozzi F, Sciacqua A, Hribal ML, Perticone F, Sesti G. Reciprocal association of plasma IGF-1 and interleukin-6 levels with cardiometabolic risk factors in nondiabetic subjects. Diabetes Care 2008;31(9):1886–8. doi: 10.2337/dc08-0553
   PubMed Web of Science ®Google Scholar
• La Du BN. Human serum paraoxonase/arylesterase. In: Kalow W, (ed.) Pharmacogenetics of drug metabolism. New York, NY: Pergamon; 1992. pp. 51–91.
   Google Scholar
• Tewthanom K, Janwityanuchit S, Totemchockyakarn K, Panomwana D. Correlation of lipid peroxidation and glutathione levels with severity of systemic lupus erythematosus: a pilot study from single center. J Pharm Pharm Sci 2008;11:30–4. doi: 10.18433/J3C885
   PubMed Web of Science ®Google Scholar
• Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996;33(3):498–507. doi: 10.1006/geno.1996.0225
   PubMed Web of Science ®Google Scholar
• Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993;52:598–608.
   PubMed Web of Science ®Google Scholar
• Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.
   PubMed Web of Science ®Google Scholar
• Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum paraoxonase/arylesterase: evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991;19(1):100–6.
   PubMed Web of Science ®Google Scholar
• Quillen EE, Rainwoter DL, Dyer TD, Carless MA, Curran JE, Johnson MP, et al. Novel associations of nonstructural Loci with paraoxonase activity. J Lipids 2012:1–7. doi: 10.1155/2012/189681
   Google Scholar
• Ng CJ, Shih DM, Hama SY, Villa N, Navab M, Reddy ST. The paraoxonase gene family and atherosclerosis. Free Radic Biol Med 2005;38:153–163. doi: 10.1016/j.freeradbiomed.2004.09.035
   PubMed Web of Science ®Google Scholar
• Mackness MI, Durrington PN. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995;115:243–53. doi: 10.1016/0021-9150(94)05524-M
   PubMed Web of Science ®Google Scholar
• Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 1998;423:57–60. doi: 10.1016/S0014-5793(98)00064-7
   PubMed Web of Science ®Google Scholar
• Sies H. Oxidative stress: introductory remarks. In: Sies H, (ed.) Oxidative stress. San Diego: Academica Press; 1985. pp. 1–7.
   Google Scholar
• Osei-Hyiaman D, Hou L, Mengbai F, Zhiyin R, Zhiming Z, Kano K. Coronary artery disease risk in Chinese type 2 diabetics: is there a role for paraxonase 1 gene (Q192R) polymorphism? Eur J Endocrinol 2001;144(6):639–44. doi: 10.1530/eje.0.1440639
   PubMed Web of Science ®Google Scholar
• Ito T, Yasue H, Yoshimura M, Nakamura S, Nakayama M, Shimasaki Y, et al. Paraoxonase gene Gln192Arg (Q192R) polymorphism is associated with coronary artery spasm. Hum Genet 2002;110(1):89–94. doi: 10.1007/s00439-001-0654-6
   PubMed Web of Science ®Google Scholar
• Arca M, Ombres D, Montali A, Campagna F, Mangieri E, Tanzilli G, et al. PON1 L55M polymorphism is not a predictor of coronary atherosclerosis either alone or in combination with Q192R polymorphism in an Italian population. Eur J Clin Invest 2002;32(1):9–15. doi: 10.1046/j.1365-2362.2002.00935.x
   PubMed Web of Science ®Google Scholar
• Ko YL, Ko YS, Wang SM, Hsu LA, Chang CJ, Chu PH, et al. The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 1998;141(2):259–64. doi: 10.1016/S0021-9150(98)00179-8
   PubMed Web of Science ®Google Scholar
• Kaman D, Ilhan N, Metin K, Akbulut M, Ustundağ BA. A preliminary study of human paraoxonase and PON 1 L/M55-PON 1 Q/R 192 polymorphisms in Turkish patients with coronary artery disease. Cell Biochem Funct 2009;27(2):88–92. doi: 10.1002/cbf.1539
   PubMed Web of Science ®Google Scholar
• Boero L, Cuniberti L, Magnani N, Manavela M, Yapur V, Bustos M, et al. Increased oxidized low density lipoprotein associated with high ceruloplasmin activity in patients with active acromegaly. Clin Endocrinol (Oxf) 2010;72(5):654–60. doi: 10.1111/j.1365-2265.2009.03685.x
   PubMed Web of Science ®Google Scholar
• Liberopoulos EN, Papavasiliou E, Miltiadous GA, Cariolou M, Siamopoulos KC, Tselepis AD, et al. Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis. Perit Dial Int 2004;24(6):580–9.
   PubMed Web of Science ®Google Scholar
• Garin MC, James RW, Dussoix P, Blanché H, Passa P, Froguel P, Ruiz J. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 1997;99(1):62–6. doi: 10.1172/JCI119134
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Suehiro T, Inoue M, Nakauchi Y, Morita T, Arii K, et al. Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Metabolism 1998;47(5):598–602. doi: 10.1016/S0026-0495(98)90246-3
   PubMed Web of Science ®Google Scholar
• Ergun MA, Yurtcu E, Demirci H, Ilhan MN, Barkar V, Yetkin I, et al. PON1 55 and 192 gene polymorphisms in type 2 diabetes mellitus patients in a Turkish population. Biochem Genet 2011;49(1–2):1–8. doi: 10.1007/s10528-010-9376-6
   PubMed Web of Science ®Google Scholar
• Altuner D, Ates I, Suzen SH, Koc GV, Aral Y, Karakaya A. The relationship of PON1 QR 192 and LM 55 polymorphisms with serum paraoxonase activities of Turkish diabetic patients. Toxicol Ind Health 2011;27(10):873–8. doi: 10.1177/0748233711399317
   PubMed Web of Science ®Google Scholar
• Alegría-Torres JA, García-Domínguez ML, Cruz M, Aradillas-García C. Q192R polymorphism of paraoxonase 1 gene associated with insulin resistance in Mexican children. Arch Med Res 2015;46(1):78–83. doi: 10.1016/j.arcmed.2014.12.001
   PubMed Web of Science ®Google Scholar